Posted inPharmaceutical
Vanda’s Experimental Social Anxiety Drug VQW-765 Fails Phase 3 Trial Endpoint
VQW-765 Phase 3 trial: no difference from placebo on public-speaking distress (65.6 vs 66.0). Design, results, caveats and what happens next.
Posted inMedical Device
FDA Classifies AVID Medical IV Start Kit Lot 1658437 Recall as Class I Over Fungal Contamination Risk
AVID Medical recall lot number: only lot 1658437 is Class I. What FDA records show, where they differ, and what hospitals must do.
Posted inHealthcare Services
Pennsylvania Measles Outbreak Reaches 1,222 Cases as CDC Sends Additional Support
Pennsylvania measles outbreak October 2026: 1,222 cases, 225 hospitalisations, five confirmed deaths and a sixth under review, as of 14 October.
Posted inHealthcare Services
West Nile Virus Cases Hit Record Levels in Europe in 2026 as Deaths Reach 130
West Nile virus deaths 2026: ECDC counts 130 deaths among 1,715 EU cases as of 7 October. Severity, risk groups, prevention and caveats.
Posted inHealthcare Services
Labcorp to Acquire BioReference Health Assets for Up to $872 Million, Expanding Diagnostic Testing
Prostate cancer 4Kscore test: Labcorp ties up to $150M of its BioReference deal to the test. What the release says and what remains undisclosed.
Posted inPharmaceutical
EMA Committee Recommends Rasonque for Metastatic Pancreatic Cancer After Phase 3 Survival Gain
Daraxonrasib pancreatic cancer: RASolute 302 shows 13.2 vs 6.7 months survival; the CHMP backs Rasonque. Trial design, side effects and caveats.
Posted inBio Technology
AstraZeneca Signs AI Drug-Discovery Deal Worth Up to $1.5 Billion With insitro
AI drug discovery 2026: AstraZeneca and insitro target MASH and heart disease. $40M upfront, up to ~$1.46B in milestones. What the platform must prove.
Posted inPharmaceutical
Zydus Sunshine Lifesciences Plans $20 Million-Plus Pharmaceutical Plant in Sri Lanka
Zydus international expansion reaches Sri Lanka: a $20M-plus plant via a joint venture, operations from 2028. How it is built and what is unclear.
Posted inPharmaceutical
First Tracks Reports Positive ANB033 Gluten-Challenge Results in Celiac Disease
ANB033 clinical trial: a CD122 antibody limited gluten-linked gut damage and symptoms in 32 celiac patients. Early data, key caveats.
Posted inLife Science
Solid Tumour Therapies Get a Promising Masked Engager Bet
Solid tumour therapies from Vir and Gilead: how masked T-cell engagers work, why solid cancers are hard, and what the $1.88B deal does not prove.